Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence

Mascilini, F.; Amadio, Giulia; Stefano, M. G. Di; Ludovisi, M.; Legge, A. Di; Conte, Carmine; Vincenzo, Rosa De; Ricci, Caterina; Masciullo, Valeria; Salutari, Vanda; Scambia, Giovanni; Ferrandina, Gabriella

doi:10.2147/ott.s51550

Cited by 9 publications

(3 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A retrospective study on 98 heavily treated ROC patients (median number of previous lines, 4; range, 1-6 lines) who received single-agent trabectedin as salvage treatment showed an ORR of 27.5%. This rate did not vary with the number of previously administered chemotherapy lines ( 14 ). The present results obtained in heavily pretreated patients (median of 3 previous lines, with some patients having received up to 10 lines) are similar to those obtained in OVA-301, where the inclusion criteria allowed only 1 previous line of treatment.…”

Section: Discussionmentioning

confidence: 90%

Trabectedin plus Pegylated Liposomal Doxorubicin: Retrospective Analysis in Heavily Pretreated Platinum-sensitive Ovarian Cancer

Nicoletto

Baldoni

Casarin

et al. 2015

Tumori

View full text Add to dashboard Cite

PurposeThis retrospective analysis evaluated treatment with trabectedin plus pegylated liposomal doxorubicin (PLD) in 34 heavily pretreated patients (median number of previous lines, 3; range, 2-10) with platinum-sensitive relapsed ovarian cancer (ROC) at a single center in Italy.MethodsTrabectedin/PLD treatment consisted of trabectedin administered every 3 weeks as a 3-hour intravenous (i.v.) infusion at a dose of 1.1 mg/m2, immediately after PLD 30 mg/m2 i.v. infusion. Study objectives were the evaluation of the objective response rate (ORR), progression-free survival (PFS) and overall survival (OS).ResultsThree complete responses and 8 partial responses were observed, with an ORR of 32.4% (95% CI, 17.450.5%). Median PFS was 6.1 months (95% CI, 4.4-8.9 months). Median OS was 16.3 months (95% CI, 6.8-23.5). Most responses (9 of 11) were found in patients with partially platinum-sensitive disease (ORR 40.9% in this subset; median PFS 6.8 months and median OS 20.8 months). Grade 3 treatment-related adverse events consisted of nausea/vomiting (n = 5; 14.7%), mucositis (n = 2; 5.9%), alanine aminotransferase increase, anemia and neutropenia (n = 1 each; 2.9%).ConclusionsThe overall findings appear consistent with those previously observed in a randomized controlled clinical trial, and support the use of trabectedin/PLD in heavily pretreated patients with platinum-sensitive ROC, especially those with partially platinum-sensitive disease.

show abstract

Section: Discussionmentioning

confidence: 90%

Trabectedin plus Pegylated Liposomal Doxorubicin: Retrospective Analysis in Heavily Pretreated Platinum-sensitive Ovarian Cancer

Nicoletto

Baldoni

Casarin

et al. 2015

Tumori

View full text Add to dashboard Cite

show abstract

“…One of these compounds, trabectedin (ET-743 or Yondelis ® , Madrid, Spain), originally isolated from the Caribbean marine tunicate Ecteinascidia turbinata , is a striking example. It has been given marketing authorization from the European Medicines Agency (EMA) and elsewhere for the treatment of advanced soft tissue sarcoma [ 71 , 72 , 73 , 74 , 75 , 76 ]. Although the percentage of marine natural products that can be developed into drugs is low, it is clear that an increasing number of marine bioactive compounds will be approved for the treatment of human diseases [ 7 , 12 , 77 ].…”

Section: Resultsmentioning

confidence: 99%

Statistical Research on the Bioactivity of New Marine Natural Products Discovered during the 28 Years from 1985 to 2012

et al. 2015

View full text Add to dashboard Cite

Every year, hundreds of new compounds are discovered from the metabolites of marine organisms. Finding new and useful compounds is one of the crucial drivers for this field of research. Here we describe the statistics of bioactive compounds discovered from marine organisms from 1985 to 2012. This work is based on our database, which contains information on more than 15,000 chemical substances including 4196 bioactive marine natural products. We performed a comprehensive statistical analysis to understand the characteristics of the novel bioactive compounds and detail temporal trends, chemical structures, species distribution, and research progress. We hope this meta-analysis will provide useful information for research into the bioactivity of marine natural products and drug development.

show abstract

“…Thus, the results of the published studies suggest the existence of a clear relationship between the duration of the PFI and overall survival (i.e., the greater the PFI, the longer the survival). As a result, the combination of trabectedin and PLD may be an effective and safe therapeutic option that could allow for lengthening the duration of the PFI and increasing the survival of these patients [2, 13].…”

Section: Discussionmentioning

confidence: 99%

Maintenance with Trabectedin in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer

et al. 2019

View full text Add to dashboard Cite

Ovarian cancer is the seventh most common type of cancer and the fifth leading cause of cancer death among women worldwide. The current usual therapeutic approach in this disease includes optimal cytoreductive therapy followed by platinum-based adjuvant chemotherapy, along with neoadjuvant chemotherapy prior to surgery in selected cases. The platinum-free interval (PFI) continues to be the most useful tool to assist in the selection of the subsequent therapy and to predict response to treatment. The combination of trabectedin and pegylated liposomal doxorubicin (PLD) is useful in patients with partially platinum-sensitive recurrent ovarian cancer, in patients who have previously received two or more platinum-based chemotherapy regimens, in patients who have already experienced a platinum-induced hypersensitivity reaction and in patients who have previously failed to respond to a platinum-based treatment. Case Presentation: A 64-years-old postmenopausal woman with pain, abdominal distension, and an altered intestinal transit and with partially platinum-sensitive recurrent ovarian cancer, was successfully treated with a second line of trabectedin chemotherapy in combination with PLD, followed by trabectedin in monotherapy. This case proves the effectiveness of the combination of trabectedin and PLD and demonstrates how the administration of trabectedin, even in monotherapy, allows to maintain an adequate clinical response with good tolerance to the treatment during more than two years of drug administration.

show abstract

Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence

Cited by 9 publications

References 56 publications

Trabectedin plus Pegylated Liposomal Doxorubicin: Retrospective Analysis in Heavily Pretreated Platinum-sensitive Ovarian Cancer

Trabectedin plus Pegylated Liposomal Doxorubicin: Retrospective Analysis in Heavily Pretreated Platinum-sensitive Ovarian Cancer

Statistical Research on the Bioactivity of New Marine Natural Products Discovered during the 28 Years from 1985 to 2012

Maintenance with Trabectedin in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer

Contact Info

Product

Resources

About